Cardiovascular Drug Could Deliver Esophageal Cancer Treatments

Phase II study results from French biotech Cerenis Therapeutics show that a drug initially developed to treat cardiovascular disease could be used to deliver treatments for esophageal cancer.

The drug, CER-001, mimics a member of a lipoprotein family called HDL, which reacts with a number of different receptors that are highly expressed in some cancers. In the Phase II trial, patients with esophageal cancer were first given a radiolabeled version of CER-001. The patients then underwent a PET-CT scan to see whether the drug targeted esophageal tumors.

Preliminary results from five patients showed the drug increased the signal from esophageal tumors by 50% in all five patients. Based on these findings, Cerenis believes CER-001 could help deliver esophageal cancer treatments to specific cellular targets. According to Cerenis, they are the first company with clinical data on HDL-based drug delivery.

Because HDL also transports cholesterol around the body, CER-001 was first developed as a cardiovascular drug. However, Cerenis failed two Phase II studies last year and in 2014 testing the same drug for treating a cardiovascular disease called post-acute coronary syndrome.

Lipoproteins like CER-001 are biodegradable, which makes them well-suited as drug-delivery compounds. Nonetheless, current lipoprotein drug delivery methods have mainly reduced treatment toxicity without increasing efficacy. While the Cerenis’ Phase II imaging results suggest CER-001 could lead to more target-specific treatments for esophageal cancer, we still have to see how it holds up when combined with a drug that actually attacks tumor tissue.

Image by Kateryna Kon/Shutterstock

Support good journalism, subscribe to Labiotech Insider

Labiotech Insider

If you liked this post and want to read more good journalism, support us by joining Labiotech Insider. Our Insider membership gives you access to exclusive content and other advantages.